ironwood pharmaceuticals inc
(IRWD:Consolidated Issue Listed on NASDAQ Global Select )
Christopher T. Walsh M.D., Ph.D.
Scientific Advisor, Director, Member of Pharmaceuticals Advisory Committee and Member of Governance & Nominating Committee, Ironwood Pharmaceuticals, Inc.
|Age||Total Calculated Compensation||This person is connected to 108 board members in 7 different organizations across 10 different industries.|
See Board Relationships
Mr. Christopher T. Walsh, also known as Chris, M.D., Ph.D., serves as a Scientific advisor of Ironwood Pharmaceuticals, Inc. Mr. Walsh serves as an Advisor of LS9, Inc. He has been Hamilton Kuhn Professor of Biological Chemistry and Molecular Pharmacology of Harvard Medical School since June 1987. He is a Co-Founder of Magen BioSciences, Inc. He served as President of the Dana-Farber Cancer Institute from 1992 to 1995. He served as Corporate Secretary of TransForm Pharmaceuticals, ...
301 Binney StreetPhone: 617-621-7722
Cambridge, Massachusetts 02142
Board Members Memberships*
Corporate Secretary and Director
Co-Founder, Director and Member of Scientific Advisory Board
Director, Chairman of Corporate Governance & Nominating Committee, Member of Compensation Committee and Member of Strategic Advisory Committee
Former Director, Member of Audit Committee, Member of Compensation Committee and Member of Nominating Committee
Scientific Advisor, Director, Member of Pharmaceuticals Advisory Committee and Member of Governance & Nominating Committee
Director and Member of Nominating & Corporate Governance Committee
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
|Michael W. Aguiar||Chief Executive Officer, President and Director|
|Howard W. Robin||Chief Executive Officer, President and Director|
|Mark R. Baker J.D.||Chief Executive Officer, Director and Member of Science & Strategy Committee|
Progenics Pharmaceuticals, Inc.
|Peter S. Greenleaf||Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee|
Sucampo Pharmaceuticals, Inc.
|A. J. Kazimi MBA||Founder, Chairman, Chief Executive Officer and President|
Cumberland Pharmaceuticals, Inc.
|$620.0K||Compensation as of Fiscal Year 2013.|